Injective Labs and 21Shares have launched the first INJ-linked Exchange Traded Product (ETP) on Euronext Amsterdam and Paris. The fund provides exposure to INJ tokens and staking rewards via major financial exchanges and brokerages.
This ETP, trading under AINJ, is supported by 25 banks and brokerages, including Interactive Brokers and Saxo Bank. It marks a significant milestone in bridging traditional finance (TradFi) and decentralized markets, paving the way for broader institutional adoption of $INJ.
AINJ, one of the few crypto tokens with an associated ETP, has $128.6 million in assets under management (AUM) and a 2.5% fee. The token offers an estimated 19.38% staking reward, subject to market changes.
The product, backed by INJ in cold storage, aligns with the Euronext Rule Book. Injective’s market cap is $2.4 billion, positioning it for increased institutional and retail participation.
This launch signifies growing interest in ETPs beyond Bitcoin, as the market anticipates Ethereum ETFs and applications for Solana-linked ETPs. This strategic advancement underscores Injective’s role in integrating crypto with traditional financial markets.
